Inclusion Criteria:  Subject is ≥ 18 years or the minimum age required for legal adult consent in the country of enrolment Subject is capable (no legally authorized representative allowed) to provide written informed consent as approved by the Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site prior to any study related procedure Subject has provided written informed consent before any study specific test or procedure and is willing to comply with all protocol and follow-up requirements De novo, restenotic, occluded or in-stent lesion(s) representing atherosclerotic lesion(s) in the iliac arteries Reference lumen (vessel) diameter between 5mm and 10 mm The target lesion can be successfully crossed with a guide wire The target lesion length is ≤ 100 mm Subjects has more than 70% stenosis in target lesion Subject has an evidence of a patent profunda femoris or superficial femoral artery in the target limb or limbs  Exclusion Criteria:  Subject is pregnant and/or breastfeeding or planning to become pregnant during the course of the study. Subject is with a current medical condition with a life expectancy of less than one year. Pre-existing target iliac artery aneurysm or perforation or dissection of the target iliac artery Any medical condition that in the opinion of the investigator poses an unacceptable risk for implant of a stent according to the study indications like, sensitivity to metal ions, has intolerance to contrast or antiplatelet, anticoagulant or thrombolytic medications required per the protocol Abdominal aortic aneurysm (AAA) contiguous to the iliac artery target lesion requiring EVAR (Endovascular Aneurysm Repair) treatment The subject is currently participating in an investigational drug, biologic, or another device study and has not reached their primary endpoint yet. Refuses blood transfusion Chronic renal insufficiency (eGFR < 30 mL/min within 72 hours prior to index procedure) Subject has IFU listed contraindication(s)